Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antisense technology: an overview and prospectus
Stanley T. Crooke, Brenda F. Baker, Rosanne M. Crooke, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 6, pp. 427-453
Closed Access | Times Cited: 499

Showing 1-25 of 499 citing articles:

The emerging roles of circRNAs in cancer and oncology
Lasse S. Kristensen, Theresa Jakobsen, Henrik Hager, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 188-206
Closed Access | Times Cited: 799
Telomere dysfunction in ageing and age-related diseases
Francesca Rossiello, Diana Jurk, João F. Passos, et al.
Nature Cell Biology (2022) Vol. 24, Iss. 2, pp. 135-147
Open Access | Times Cited: 434
RNA-based therapeutics: an overview and prospectus
Yiran Zhu, Liyuan Zhu, Xian Wang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 369
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Rik Ossenkoppele, Rik van der Kant, Oskar Hansson
The Lancet Neurology (2022) Vol. 21, Iss. 8, pp. 726-734
Open Access | Times Cited: 279
Antisense technology: A review
Stanley T. Crooke, Xue‐hai Liang, Brenda F. Baker, et al.
Journal of Biological Chemistry (2021) Vol. 296, pp. 100416-100416
Open Access | Times Cited: 236
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
Maria Gagliardi, Ana Tari Ashizawa
Biomedicines (2021) Vol. 9, Iss. 4, pp. 433-433
Open Access | Times Cited: 139
Reexamining assumptions about miRNA-guided gene silencing
Audrius Kilikevičius, Gunter Meister, David R. Corey
Nucleic Acids Research (2021) Vol. 50, Iss. 2, pp. 617-634
Open Access | Times Cited: 130
Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles
Jeremy Bost, Hanna M. G. Barriga, Margaret N. Holme, et al.
ACS Nano (2021) Vol. 15, Iss. 9, pp. 13993-14021
Open Access | Times Cited: 124
Insights into recent findings and clinical application of YAP and TAZ in cancer
James Franklin, ZhengMing Wu, Kun‐Liang Guan
Nature reviews. Cancer (2023) Vol. 23, Iss. 8, pp. 512-525
Closed Access | Times Cited: 104
RNA editing: Expanding the potential of RNA therapeutics
Brian J. Booth, Sami Nourreddine, Dhruva Katrekar, et al.
Molecular Therapy (2023) Vol. 31, Iss. 6, pp. 1533-1549
Open Access | Times Cited: 83
RNA therapeutics: updates and future potential
Caroline Zhang, Biliang Zhang
Science China Life Sciences (2022) Vol. 66, Iss. 1, pp. 12-30
Open Access | Times Cited: 81
Transcription of MERVL retrotransposons is required for preimplantation embryo development
Akihiko Sakashita, Tomohiro Kitano, Hirotsugu Ishizu, et al.
Nature Genetics (2023) Vol. 55, Iss. 3, pp. 484-495
Open Access | Times Cited: 80
Delivery of RNA Therapeutics: The Great Endosomal Escape!
Steven F. Dowdy, Ryan L. Setten, Xian-Shu Cui, et al.
Nucleic Acid Therapeutics (2022) Vol. 32, Iss. 5, pp. 361-368
Open Access | Times Cited: 74
Amplifying gene expression with RNA-targeted therapeutics
Olga Khorkova, Jack Stahl, Aswathy Joji, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 539-561
Open Access | Times Cited: 69
Targeting and engineering long non-coding RNAs for cancer therapy
Michela Coan, Simon Haefliger, Samir Ounzain, et al.
Nature Reviews Genetics (2024) Vol. 25, Iss. 8, pp. 578-595
Closed Access | Times Cited: 64
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
Steven F. Dowdy
RNA (2023) Vol. 29, Iss. 4, pp. 396-401
Open Access | Times Cited: 62
Nucleic acid drug vectors for diagnosis and treatment of brain diseases
Zhiguo Lü, Jie Shen, H. J. Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 61
RNA‐based medicine: from molecular mechanisms to therapy
Anke Sparmann, Jörg Vogel
The EMBO Journal (2023) Vol. 42, Iss. 21
Open Access | Times Cited: 55
Roles of lncRNAs in brain development and pathogenesis: Emerging therapeutic opportunities
Tara Srinivas, Carolina Mathias, Cristina Oliveira-Mateos, et al.
Molecular Therapy (2023) Vol. 31, Iss. 6, pp. 1550-1561
Open Access | Times Cited: 49
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Xiaoyu Chen, Fikri Birey, Min-Yin Li, et al.
Nature (2024) Vol. 628, Iss. 8009, pp. 818-825
Open Access | Times Cited: 46
Chemically Modified Platforms for Better RNA Therapeutics
Yesi Shi, Xueyan Zhen, Yiming Zhang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 3, pp. 929-1033
Closed Access | Times Cited: 44
N4-acetylcytidine modification of lncRNA CTC-490G23.2 promotes cancer metastasis through interacting with PTBP1 to increase CD44 alternative splicing
Xiaomei Yu, Shujun Li, Ziting Yao, et al.
Oncogene (2023) Vol. 42, Iss. 14, pp. 1101-1116
Closed Access | Times Cited: 43
Small molecule approaches to targeting RNA
Sandra Kovachka, Marc Panosetti, Benedetto Grimaldi, et al.
Nature Reviews Chemistry (2024) Vol. 8, Iss. 2, pp. 120-135
Open Access | Times Cited: 36
Engineering approaches for RNA-based and cell-based osteoarthritis therapies
Carlisle R. DeJulius, Bonnie L. Walton, Juan M. Colazo, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 81-100
Closed Access | Times Cited: 28
A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer
Katia Grillone, Giulio Caridà, Francesco Luciano, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top